High Neutrophil/Lymphocyte ratio (NLR), as a measure of enhanced inflammatory response, has been negatively associated with prognosis in patients with localized pancreatic ductal adenocarcinoma (PDA).
OBJECTIVE:
In the present study, we aimed at investigating the prognostic value of NLR in two homogeneous groups of chemotherapy-naïve metastatic PDA patients. Patients were treated with either gemcitabine (GEM) or gemcitabine/oxaliplatin (GEMOXA). We also assessed whether NLR could identify patients benefiting from the use of oxaliplatin.
METHODS:
Consecutive PDA patients treated at the Medical Oncology Unit of Tor Vergata University Hospital of Rome with either GEM or GEMOXA were included(n= 103). NLR was assessed before and during chemotherapy and correlated with outcome together with common clinical and biochemical variables.
RESULTS:
Among 17 analyzed variables NLR, Karhofsky Perfomance Status (KPS), d-dimer and erythrocyte sedimentation rate were found to be significantly associated with median Overall Survival (mOS) at the univariate analysis. Only NLR and KPS were independent prognosticator at multivariate analysis, with NLR displaying the highest statistical significance. NLR was also predictive of oxaliplatin activity, as only patients with NLR > 2.5 (cutoff determined upon ROC analysis) derived benefit from GEMOXA over GEM.
CONCLUSIONS:
NLR is both an independent prognostic and predictive factor in metastatic PDA, since only patients with high NLR seem to benefit from the addition of oxaliplatin. NLR may help select patients for whom a particularly poor prognosis might justify more intensive, yet less tolerable, combination regimens.
HamadaT, NakaiY, YasunagaH, IsayamaH, MatsuiH, TakaharaN, SasakiT, TakagiK, WatanabeT, YagiokaH, KogureH, ArizumiT, YamamotoN, ItoY, HiranoK, TsujinoT, TadaM and KoikeK, Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy, Br J Cancer110 (2014), 1943-1949.
2.
SeufferleinT, BachetJB, Van CutsemE and RougierP, ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol23(Suppl 7) (2012), vii33-40.
3.
BerlinJD et al., Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297, J Clin Oncol20 (2002), 3270-3275.
4.
Rocha LimaCM et al., Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate, J Clin Oncol22 (2004), 3776-3783.
5.
LouvetC et al., Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial, J Clin Oncol23 (2005), 3509-3516.
6.
HeinemannV et al., Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer, J Clin Oncol24 (2006), 3946-3952.
7.
HerrmannR et al., Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group, J Clin Oncol25 (2007), 2212-2217.
8.
PoplinE et al., Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group, J Clin Oncol27 (2009), 3778-3785.
9.
KindlerHL et al., Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303), J Clin Oncol28 (2010), 3617-3622.
10.
ColucciG et al., Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study, J Clin Oncol28 (2010), 1645-1651.
11.
CunninghamD et al., Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, J Clin Oncol27 (2009), 5513-5518.
12.
PhilipPA et al., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205, J Clin Oncol28 (2010), 3605-3610.
13.
SultanaA, SmithCT, CunninghamD, StarlingN, NeoptolemosJP and GhanehP, Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer, J Clin Oncol25 (2007), 2607-2615.
14.
ConroyT, DesseigneF, YchouM, BouchéO, GuimbaudR and BécouarnY, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med364 (2011), 1817-1825.
15.
GoldsteinD, El-MaraghiRH, HammelP, HeinemannV, KunzmannV and SastreJ, nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial, J Natl Cancer Inst107 (2015), pii.
16.
BelliaA, GarcovichC, D'AdamoM, LombardoM, TesauroM and DonadelG, Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects, Intern Emerg Med8 (2013), 33-40.
17.
BrevettiG, GiuglianoG, BrevettiL and HiattWR, Inflammation in peripheral artery disease, Circulation122 (2010), 1862-1875.
18.
RedlichK and SmolenJS, Inflammatory bone loss: Pathogenesis and therapeutic intervention, Nat Rev Drug Discov11 (2012), 234-250.
19.
GuadagniF, FerroniP, PalmirottaR, Del MonteG, FormicaV and RoselliM, Non-steroidal anti-inflammatory drugs in cancer prevention and therapy, Anticancer Res27 (2007), 3147-3162.
20.
GuadagniF, FerroniP, PalmirottaR, PortarenaI, FormicaV and RoselliM, Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: An early target in anticancer therapeutic strategy, In Vivo21 (2007), 147-161.
21.
FormicaV, CeredaV, di BariMG, GrengaI, TesauroM and RaffaeleP, Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B), Med Oncol30 (2013), 743.
22.
FormicaV, CeredaV, NardecchiaA, TesauroM and RoselliM, Immune reaction and colorectal cancer: friends or foes?World J Gastroenterol20 (2014), 12407-12419.
23.
FormicaV, LuccchettiJ, CunninghamD, SmythEC, FerroniP and NardecchiaA, Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients, Med Oncol31 (2014), 166.
24.
SanjayP, de FigueiredoRS, LeaverH, OgstonS, KulliC and PolignanoFM, Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, JOP13 (2012), 199-204.
25.
HessV et al., CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial, Lancet Oncol9 (2008), 132-138.
26.
StockenDD et al., Modelling prognostic factors in advanced pancreatic cancer, Br J Cancer99 (2008), 883-893.
27.
LiuP, ZhuY, LiuL et al., Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma, Onco Targets Ther8 (2015), 1335-1340.
28.
ShinyA, BibinYS, ShanthiraniCS, ReginBS, AnjanaRM and BalasubramanyamM, Association of Neutrophil-Lymphocyte Ratio with Glucose Intolerance: An Indicator of Systemic Inflammation in Patients with Type 2 Diabetes, Diabetes Technol Ther16 (2014), 524-30.
29.
HamedMO, RobertsKJ, SmithAM and Morris StiffG, Elevated pre-operative neutrophil to lymphocyte ratio predicts disease free survival following pancreatic resection for periampullary carcinomas, Pancreatology13 (2013), 534-538.
30.
GarceaG, LadwaN, NealCP, MetcalfeMS, DennisonAR and BerryDP, Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma, World J Surg35 (2011), 868-872.
31.
SzkanderaJ, StotzM, EisnerF, AbsengerG, StojakovicT and SamoniggH, External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients, PLoS One8 (2013), e78225.
32.
SzkanderaJ, StotzM, AbsengerG, StojakovicT, SamoniggH and KornpratP, Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients, Br J Cancer110 (2014), 183-188.
33.
XueP, KanaiM, MoriY, NishimuraT, UzaN and KodamaY, Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients, Cancer Med3 (2014), 406-415.
34.
AnX, DingPR, LiYH, WangFH, ShiYX and WangZQ, Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer, Biomarkers15 (2010), 516-522.
35.
TeoM, Mohd SharialMS, McDonnellF, ConlonKC and RidgwayPF, Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy, Tumori99 (2013), 516-522.
36.
LuoG, GuoM, LiuZ, XiaoZ, JinK, LongJ, LiuL, LiuC, XuJ, NiQ and YuX, Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy, Ann Surg Oncol22 (2015), 670-676.
37.
StotzM, GergerA, EisnerF, SzkanderaJ, LoibnerH and RessAL, Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer, Br J Cancer109 (2013), 416-421.
38.
ClarkeS, BurgeM, CordwellC, GibbsP, ReeceW and TebbuttN, An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT], BMC Cancer13 (2013), 120.
39.
KantolaT, KlintrupK, VäyrynenJP, VornanenJ, BloiguR and KarhuT, Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma, Br J Cancer107 (2012), 1729-1736.
